Skip to the content
Search
Beyond Type 1
Menu
BEYOND TYPE 1
Show sub menu
About
Board of Directors
The Team
Leadership Council
Portfolio
Press
Careers
Contact
Join Us
Diabetes
Type 1 Info
Type 2 Info
Diabetes Management
Newly Diagnosed
Forms Of Diabetes
Autoimmune Diseases
Pregnancy with Type 1 Diabetes
Research
Resources
Stories
Diabetes News
Diabetes Management
Diabetes + Exercise
Mental Health + Diabetes
Food and Diabetes
School Resources
Sex, Drugs + Rock & Roll
Travel + Adventure
Previously Healthy
GetInsulin.org
Newsletter
Programs
Beyond Type 1 App
Beyond Barriers
Beyond Scholars
Community Table
GetInsulin.org
Marathon Team
Snail Mail Club
TuDiabetes
Type 1 Signs
Jesse Was Here
Advocacy
Donate
Search
Tag:
Breaking News
Senseonics + UnitedHealthcare Expanding CGM Access
Senseonics announced that UnitedHealthCare will now cover their Eversense E3 implantable CGM, starting July 1, 2023.
Medtronic’s MiniMed 780G Receives FDA Approval
The FDA has approved Medtronic’s MiniMed 780G, the newest automated insulin dosing (AID) system on the market.
Eli Lilly’s Baqsimi Acquired by Amphastar: What This Means for People With Diabetes
Eli Lilly’s nasal glucagon, Baqsimi, has been acquired by Amphastar. Here’s what you should know about the change and its significance.
Freestyle Libre 2 and Freestyle Libre 3 to Integrate with Automated Insulin Delivery Systems
Abbott, makers of the Freestyle Libre 2 and 3, modified their sensors to enable integration with automated insulin delivery systems. Here’s what you should know!
FDA Approves Teplizumab to Delay Onset of Type 1 Diabetes
Teplizumab binds to certain immune system cells and delays the progression of T1D.
Your Doctor May Start Screening for Anxiety. Here’s Why.
Your mental health should be a part of your ongoing diabetes care—after all, anxiety is more common among people with diabetes.
Vertex Acquires ViaCyte, Combining Resources Toward a T1D Cure
The global biotech giant is set to acquire ViaCyte for $320 million.
COVID-19 Pushes FDA Approval of Breakthrough Device Designation for Dexcom CGM in Hospital Settings
The FDA has granted Breakthrough Device Designation for Dexcom CGM in hospital settings after the pandemic highlighted essential care needs for patients with diabetes.
Eversense E3 Continuous Glucose Monitor Gains FDA Approval, Offers Extended Wear-Time
The Eversense E3 continuous glucose monitor (CGM) is an exciting advancement for the diabetes community, with improved wear-time and accuracy.
FDA Issues CRL for Teplizumab, Investigational Candidate to Delay the Onset of T1D
The FDA issues a complete response letter to Provention Bio as part of an update for Teplizumab to delay the onset of type 1 diabetes.
Walmart Launches Lower-Cost Analog Insulin: ReliOn NovoLog
ReliOn NovoLog will be available at Walmart and Sam's Club pharmacies for $72.88 per vial and $85.88 per box of five FlexPens.
Breaking News From ATTD 2021
This year, ATTD 2021 will be held virtually where developers and clinicians will present their new diabetes technology and research.
FDA Advisory Committee Votes 10-7 To Recommend Approval of Teplizumab For Delay Of Type 1 Diabetes
Teplizumab is an investigational candidate proven to delay the onset of type 1 diabetes. The FDA advisory committee reviews its efficacy.
United Healthcare to Begin Covering Tandem Insulin Pumps
On July 1, 2020, United Healthcare (UHC) announced they will begin covering the Tandem t:slim X2 insulin pump, a departure from UHC’s four-year policy to only provide health insurance coverage for M...